Prima BioMed's CVac(TM) Data Demonstrating Improvement in PFS in Second Remission Ovarian Cancer Accepted for Oral Presentation at ASCO
March 27, 2014 21:40 ET
|
Prima BioMed
SYDNEY, AUSTRALIA--(Marketwired - Mar 27, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima") announced today that the American Society of Clinical Oncology has accepted the abstract...
Prima BioMed Announces Significant Updates to Its Clinical Advisory Board: Eric Pujade-Lauraine, Christian Marth, and Ignace Vergote Join Esteemed Group of Gynecology Oncology Advisors
March 25, 2014 09:37 ET
|
Prima BioMed
SYDNEY, AUSTRALIA--(Marketwired - Mar 25, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima," "the Company") announced today that Professors Eric Pujade-Lauraine, MD, PhD, Christian Marth,...
$1.6 Million R&D Tax Incentive Refund Received
March 05, 2014 09:23 ET
|
Prima BioMed
SYDNEY, AUSTRALIA--(Marketwired - Mar 5, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima," "the Company") is pleased to advise that it has received approximately...
Prima BioMed to Present at Regen Med Investor Day March 26th in New York
February 26, 2014 20:15 ET
|
Prima BioMed
SYDNEY, AUSTRALIA--(Marketwired - Feb 26, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima," "the Company") will present at the 2nd Annual Regen Med Investor Day to be held Wednesday,...
Prima BioMed to Present at 24th Annual Wall Street Analyst Forum Institutional Investor Conference
February 26, 2014 17:30 ET
|
Prima BioMed
SYDNEY, AUSTRALIA--(Marketwired - Feb 26, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima," "the Company") will present a corporate overview and provide an update of its CVac™...
Prima BioMed and Neopharm Group Execute Final Agreement for CVac License
February 20, 2014 17:07 ET
|
Prima BioMed
SYDNEY, AUSTRALIA--(Marketwired - Feb 20, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company") is pleased to announce that it has finalized an agreement with Neopharm Group...
Dr. Bradley J. Monk to Join Prima BioMed's Clinical Advisory Board
February 19, 2014 19:05 ET
|
Prima BioMed
SYDNEY, AUSTRALIA--(Marketwired - Feb 19, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima," "the Company") announced today that Bradley J. Monk, MD, an esteemed clinical researcher and...
Pete A. Meyers to Join Prima BioMed's Board of Directors
February 11, 2014 18:45 ET
|
Prima BioMed
SYDNEY, AUSTRALIA--(Marketwired - Feb 11, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company") is pleased to announce that Pete A. Meyers will join Prima's Board as a...
Prima BioMed's CAN-004 Clinical Trial Amendment Approved in Multiple Jurisdictions
February 05, 2014 17:00 ET
|
Prima BioMed
SYDNEY, AUSTRALIA--(Marketwired - Feb 5, 2014) - Prima BioMed Ltd. (ASX: PRR) (NASDAQ: PBMD) ("Prima," the "Company") announced that multiple jurisdictions have approved its amended CAN-004...
Prima BioMed to Present at the 16th Annual BIO CEO & Investor Conference
January 30, 2014 21:20 ET
|
Prima BioMed
SYDNEY, AUSTRALIA--(Marketwired - Jan 30, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", "the Company") has announced today that Matthew Lehman, its Chief...